Latest Insider Transactions at Coherus Bio Sciences, Inc. (CHRS)
This section provides a real-time view of insider transactions for Coherus Bio Sciences, Inc. (CHRS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Coherus BioSciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Coherus BioSciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2024
|
Mats Wahlstrom |
BUY
Bona fide gift
|
Indirect |
99,988
+50.0%
|
-
|
|
Feb 09
2024
|
Mats Wahlstrom |
SELL
Bona fide gift
|
Direct |
99,988
-100.0%
|
-
|
|
Feb 01
2024
|
Mats Wahlstrom |
BUY
Exercise of conversion of derivative security
|
Direct |
59,988
+26.23%
|
$59,988
$1.67 P/Share
|
|
Jan 20
2024
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,854
-5.64%
|
$9,708
$2.44 P/Share
|
|
Jan 20
2024
|
Dennis M Lanfear President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,218
-1.56%
|
$22,436
$2.44 P/Share
|
|
Jan 20
2024
|
Bryan J Mc Michael Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,707
-6.92%
|
$3,414
$2.44 P/Share
|
|
Jan 07
2024
|
Bryan J Mc Michael Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,707
-6.47%
|
$3,414
$2.87 P/Share
|
|
Jan 04
2024
|
Dennis M Lanfear President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,781
-1.61%
|
$23,562
$2.92 P/Share
|
|
Jan 04
2024
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,275
-2.57%
|
$4,550
$2.92 P/Share
|
|
Dec 31
2023
|
Mc David Stilwell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,440
-19.67%
|
$55,320
$3.33 P/Share
|
|
Dec 13
2023
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,049
-2.27%
|
$4,098
$2.37 P/Share
|
|
Nov 22
2023
|
Dennis M Lanfear President & CEO |
SELL
Open market or private sale
|
Direct |
223,100
-23.37%
|
$446,200
$2.02 P/Share
|
|
Nov 22
2023
|
Dennis M Lanfear President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
299,940
+13.45%
|
$299,940
$1.42 P/Share
|
|
Apr 01
2023
|
Mc David Stilwell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,457
-3.27%
|
$20,742
$6.84 P/Share
|
|
Apr 01
2023
|
Paul Reider Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,451
-2.74%
|
$14,706
$6.84 P/Share
|
|
Mar 31
2023
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,278
-12.27%
|
$97,668
$6.84 P/Share
|
|
Jan 20
2023
|
Dennis M Lanfear President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
86,250
+11.64%
|
-
|
|
Jan 20
2023
|
Mc David Stilwell Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+27.73%
|
-
|
|
Jan 20
2023
|
Vladimir Vexler Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+23.35%
|
-
|
|
Jan 20
2023
|
Bryan J Mc Michael Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.15%
|
-
|
|
Jan 11
2023
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,602
-3.79%
|
$36,020
$10.26 P/Share
|
|
Jan 10
2023
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,602
-3.66%
|
$32,418
$9.85 P/Share
|
|
Jan 07
2023
|
Bryan J Mc Michael Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,699
-10.9%
|
$15,291
$9.58 P/Share
|
|
Jan 04
2023
|
Mc David Stilwell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,437
-7.8%
|
$48,933
$9.87 P/Share
|
|
Jan 04
2023
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,437
-5.23%
|
$48,933
$9.87 P/Share
|
|
Jan 04
2023
|
Dennis M Lanfear President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,905
-1.88%
|
$98,145
$9.87 P/Share
|
|
Dec 30
2022
|
Dennis M Lanfear President & CEO |
SELL
Bona fide gift
|
Indirect |
4,000
-0.92%
|
-
|
|
Apr 01
2022
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-3.22%
|
$41,496
$12.85 P/Share
|
|
Apr 01
2022
|
Mc David Stilwell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-4.73%
|
$41,496
$12.85 P/Share
|
|
Feb 28
2022
|
Mats Wahlstrom |
BUY
Grant, award, or other acquisition
|
Direct |
29,994
+42.85%
|
$59,988
$2.08 P/Share
|
|
Feb 25
2022
|
Mats Wahlstrom |
BUY
Grant, award, or other acquisition
|
Direct |
10,006
+50.0%
|
$110,066
$11.64 P/Share
|
|
Jan 11
2022
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,583
-3.23%
|
$50,162
$14.36 P/Share
|
|
Jan 10
2022
|
Vladimir Vexler Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-3.6%
|
$58,100
$14.3 P/Share
|
|
Jan 04
2022
|
Vladimir Vexler Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+25.78%
|
-
|
|
Jan 04
2022
|
Mc David Stilwell Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+35.36%
|
-
|
|
Jan 04
2022
|
Dennis M Lanfear President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
86,250
+12.96%
|
-
|
|
Nov 17
2021
|
Dennis M Lanfear President & CEO |
SELL
Bona fide gift
|
Indirect |
10,000
-2.24%
|
-
|
|
Oct 15
2021
|
Mc David Stilwell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,507
-9.99%
|
$56,112
$16.8 P/Share
|
|
Sep 29
2021
|
James Healy Director |
SELL
Open market or private sale
|
Indirect |
286,076
-100.0%
|
$4,577,216
$16.12 P/Share
|
|
Sep 28
2021
|
James Healy Director |
SELL
Open market or private sale
|
Indirect |
48,329
-14.45%
|
$821,593
$17.17 P/Share
|
|
Sep 27
2021
|
James Healy Director |
SELL
Open market or private sale
|
Indirect |
100,150
-23.05%
|
$1,802,700
$18.06 P/Share
|
|
Jul 06
2021
|
Vincent R Anicetti Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+28.61%
|
-
|
|
Jun 09
2021
|
Mc David Stilwell Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,700
+9.53%
|
$48,100
$13.42 P/Share
|
|
Jun 08
2021
|
Dennis M Lanfear President & CEO |
SELL
Open market or private sale
|
Direct |
31,054
-5.92%
|
$403,702
$13.56 P/Share
|
|
Jun 08
2021
|
Dennis M Lanfear President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,054
+5.59%
|
$0
$0.42 P/Share
|
|
Jun 06
2021
|
Dennis M Lanfear President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+37.82%
|
$0
$0.42 P/Share
|
|
Apr 28
2021
|
Vladimir Vexler Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+21.42%
|
-
|
|
Apr 28
2021
|
Mc David Stilwell Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+40.0%
|
-
|
|
Apr 28
2021
|
Vincent R Anicetti Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+21.41%
|
-
|
|
Mar 09
2021
|
Vladimir Vexler Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
114,240
-68.15%
|
$1,827,840
$16.25 P/Share
|